TellWell
…
← Misinformation tracker
UnverifiableNews · Health

Yes, There Is Still No Approved Drug That Can Stop Osteoarthritis — Here's What That Means

“Currently, there is no approved medication that can slow, stop, or reverse the underlying disease process of osteoarthritis”

The argument in brief

The claim is true: as of 2024, no medication approved by the FDA or its European equivalent can slow, stop, or reverse the joint damage caused by osteoarthritis. Every approved treatment — from anti-inflammatory pills to steroid injections — only manages pain and stiffness. The Arthritis Foundation, the American College of Rheumatology, and multiple peer-reviewed reviews all confirm this gap.

Why it spread

This one is unusual — it spreads because it is accurate and emotionally resonant. Millions of patients have been told by their doctors that nothing can stop their disease from progressing, which is both devastating and motivating. Advocacy groups and researchers repeat it loudly to highlight an urgent unmet need and push for more funding. The frustration it captures is real, which is exactly why it travels so easily.

The claim is accurate, and it matters. Despite osteoarthritis affecting hundreds of millions of people worldwide, not a single drug has been approved as a disease-modifying osteoarthritis drug — what researchers call a DMOAD. That means no approved medication can slow the breakdown of cartilage, halt structural joint changes, or reverse any part of the underlying disease process.

Every treatment currently on the market targets symptoms, not the disease itself. NSAIDs reduce inflammation and pain. Corticosteroid injections calm flare-ups. Hyaluronic acid injections aim to lubricate the joint. Duloxetine can help with chronic pain signals. All of these can meaningfully improve quality of life — but none of them touch what is actually happening inside the joint.

This is not for lack of trying. According to a 2021 review in Nature Reviews Rheumatology and a separate analysis in NEJM Evidence, the field has seen decades of research and dozens of late-stage clinical trials, all of which have failed to produce a drug that meets the regulatory bar for disease modification. Candidates like sprifermin and lorecivivint generated real scientific interest but did not clear the hurdle for approval in the US or EU.

The American College of Rheumatology's clinical guidelines reflect this reality directly: their osteoarthritis recommendations cover only symptom management, because there is simply nothing else approved to recommend. The Osteoarthritis and Cartilage Journal has published similar confirmations, noting no pharmacological agent has demonstrated sufficient structural benefit to gain regulatory approval.

This claim spreads widely — but unlike most medical misinformation, it spreads because it is true and important. Patient advocacy groups and rheumatologists repeat it to set honest expectations and to push for more research funding. If you hear someone promoting a supplement or injection as something that 'repairs cartilage' or 'reverses arthritis,' that is the red flag. No such product has cleared the evidence bar that would earn regulatory approval.

Sources

  • U.S. Food and Drug Administration (FDA)

    In 2023, the FDA approved sprifermin... wait, actually the FDA has not approved any disease-modifying osteoarthritis drug (DMOAD). Current approvals are only for symptom management. Note: Lorecivivint and sprifermin have not received FDA approval as DMOADs.

  • Arthritis Foundation

    The Arthritis Foundation confirms that no disease-modifying osteoarthritis drugs (DMOADs) have been approved by the FDA; all current treatments focus on pain relief and improving function rather than altering disease progression.

  • Nature Reviews Rheumatology - DMOAD Review

    A 2021 peer-reviewed review confirmed that despite decades of research and numerous clinical trials, no DMOAD has successfully completed the regulatory approval process, and the field continues to lack a disease-modifying therapy for osteoarthritis.

  • Osteoarthritis and Cartilage Journal

    Published research confirms that as of recent years, no pharmacological agent has demonstrated sufficient efficacy in slowing structural progression of osteoarthritis to gain regulatory approval as a DMOAD in the US or EU.

  • American College of Rheumatology (ACR)

    ACR guidelines for osteoarthritis management focus entirely on symptom management (NSAIDs, corticosteroids, physical therapy), with no DMOAD listed, reflecting the absence of any approved disease-modifying treatment.

  • NEJM Evidence - Osteoarthritis Drug Development

    A review in NEJM Evidence highlights that the osteoarthritis drug pipeline has seen repeated late-stage clinical trial failures, and no compound has achieved regulatory approval for disease modification as of the current date.

TellWell AI

Related debunks